Warren, R. B. et al. (2015) Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British association of dermatologists biologic interventions register (BADBIR). Journal of Investigative Dermatology, 135(11), pp. 2632-2640. (doi: 10.1038/jid.2015.208) (PMID:26053050)
Full text not currently available from Enlighten.
Abstract
Drug survival reflects a drug’s effectiveness, safety, and tolerability. We assessed the drug survival of biologics used to treat psoriasis in a prospective national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register (BADBIR)). The survival rates of the first course of biologics for 3,523 biologic-naive patients with chronic plaque psoriasis were compared using survival analysis techniques and predictors of discontinuation analyzed using a multivariate Cox proportional hazards model. Data for patients on adalimumab (n=1,879), etanercept (n=1,098), infliximab (n=96), and ustekinumab (n=450) were available. The overall survival rate in the first year was 77%, falling to 53% in the third year. Multivariate analysis showed that female gender (hazard ratio (HR) 1.22; 95% confidence interval (CI): 1.09–1.37), being a current smoker (HR 1.19; 95% CI: 1.03–1.38), and a higher baseline dermatology life quality index (HR 1.01; 95% CI: 1.00–1.02) were predictors of discontinuation. Presence of psoriatic arthritis (HR 0.82; 95% CI: 0.71–0.96) was a predictor for drug survival. As compared with adalimumab, patients on etanercept (HR 1.63; 95% CI: 1.45–1.84) or infliximab (HR 1.56; 95% CI: 1.16–2.09) were more likely to discontinue therapy, whereas patients on ustekinumab were more likely to persist (HR 0.48; 95% CI: 0.37–0.62). After accounting for relevant covariates, ustekinumab had the highest first-course drug survival. The results of this study will aid clinical decision making when choosing biologic therapy for psoriasis patients.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Burden, Professor David |
Authors: | Warren, R. B., Smith, C. H., Yiu, Z. Z.N., Ashcroft, D. M., Barker, J. N.W.N., Burden, D., Lunt, M., McElhone, K., Ormerod, A. D., Owen, C. M., Reynolds, N. J., and Griffiths, C. E.M. |
College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
Journal Name: | Journal of Investigative Dermatology |
Publisher: | Nature Publishing Group |
ISSN: | 0022-202X |
ISSN (Online): | 1523-1747 |
University Staff: Request a correction | Enlighten Editors: Update this record